(LLY)

Danish drugmaker Novo Nordisk A/S (CPH: NOVO-B) lost more than 10% last week after its US rival Eli Lilly & Co (NYSE: LLY) reported encouraging Phase 3 data for its oral weight-loss treatment.  Lilly'...

Eli Lilly's stock price rise of 9% YTD might not look like a lot on its own, but in the context of the recent market decline, it's still a standout performance. With no end in sight for market uncerta...

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Eli Lilly's stock surges as its investigational oral GLP-1 pill, orforglipron, achieves the primary and key secondary goals in the first late-stage study for adults with T2D.

Healthcare ETFs split as insurers stumble and pharma surges -- highlighting the necessity of smart industry picks.

Lilly (LLY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down ...

The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.

Novo Nordisk (NVO -7.78%) has seen revenue soar in recent years thanks to two drugs that have helped people around the world lose weight. The molecule is semaglutide, and it's sold under the name Ozem...

Eli Lilly's recent Phase III results for its oral weight loss pill have demonstrated remarkable results. LLY has emerged as the frontrunner to tap into the next stage of growth through Orforglipron, p...

Drugmaker Eli Lilly (LLY 14.56%) hasn't been exempt from the recent market pullback, but its stock shot higher following the announcement that its newest GLP-1 drug had successfully completed the firs...